Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Pain, Postoperative 4Lung Neoplasms 3Breast Neoplasms 3Stomach Neoplasms 2Pain 2Lymphoma 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Thyroid Neoplasms 1Supratentorial Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Postoperative Hemorrhage 1Polyposis, Gastric 1Oropharyngeal Neoplasms 1Nerve Block 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Musculoskeletal Diseases 1Multiple Myeloma 1Mouth Neoplasms 1Malignant Neoplasms of Male Genital Organs 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Leukemia, Hairy Cell 1Leukemia 1Leiomyoma 1Hypotension 1Hodgkin Disease 1

Interventions

Dexamethasone 809Bortezomib 449Lenalidomide 430Cyclophosphamide 336Melphalan 251Calcium Dobesilate 237daratumumab 218pomalidomide 202carfilzomib 181fludarabine phosphate 131Thalidomide 121fludarabine 118Peripheral Blood Stem Cell Transplantation 117Filgrastim 111ixazomib 85Mycophenolic Acid 85Granulocyte Colony-Stimulating Factor 84Busulfan 83Whole-Body Irradiation 80Tacrolimus 75dexamethasone acetate 74Cyclosporine 67isatuximab 64Prednisone 64dexamethasone 21-phosphate 63elotuzumab 60auricularum 57belantamab mafodotin 55Antilymphocyte Serum 55Etoposide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Multiple Myeloma × Epinephrine × Clear all
NCT02356159 2025-09-30

Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
34 enrolled 18 charts
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡